Inozyme Pharma (NASDAQ:INZY) Given “Buy” Rating at HC Wainwright

Inozyme Pharma (NASDAQ:INZY)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $14.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 185.13% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group reissued a “buy” rating and set a $17.00 price objective (up previously from $16.00) on shares of Inozyme Pharma in a report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Inozyme Pharma in a report on Friday. Wedbush reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Inozyme Pharma in a research note on Monday, September 30th. Finally, Stifel Nicolaus started coverage on Inozyme Pharma in a research report on Thursday, September 12th. They set a “buy” rating and a $16.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $16.14.

Inozyme Pharma Stock Performance

Shares of INZY stock opened at $4.91 on Friday. The company has a current ratio of 9.84, a quick ratio of 9.84 and a debt-to-equity ratio of 0.48. The stock has a 50 day simple moving average of $5.28 and a 200-day simple moving average of $4.97. The company has a market cap of $303.71 million, a price-to-earnings ratio of -3.58 and a beta of 1.51. Inozyme Pharma has a 12-month low of $2.69 and a 12-month high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). On average, equities analysts forecast that Inozyme Pharma will post -1.68 EPS for the current year.

Institutional Investors Weigh In On Inozyme Pharma

A number of large investors have recently bought and sold shares of INZY. Vanguard Group Inc. lifted its position in shares of Inozyme Pharma by 1.4% in the first quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock valued at $18,530,000 after acquiring an additional 33,998 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in Inozyme Pharma by 40.1% in the 1st quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock valued at $20,242,000 after purchasing an additional 756,717 shares during the last quarter. Kennedy Capital Management LLC lifted its holdings in Inozyme Pharma by 52.2% in the 1st quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock valued at $3,352,000 after purchasing an additional 150,120 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Inozyme Pharma during the 2nd quarter worth about $76,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Inozyme Pharma by 16.1% during the second quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock worth $851,000 after buying an additional 26,464 shares in the last quarter. Institutional investors and hedge funds own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.